Clinical trials: Malignant Solid Tumours
Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
This phase I trial investigates the side effects and best dose of talazoparib when given together with trifluridine/tipiracil for the treatment of patients with colorectal or gastroesophageal cancer that has spread to nearby…
- Conditions
- Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT04511039
- Testing
- Trifluridine and Tipiracil Hydrochloride, Talazoparib Tosylate
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Roswell Park Cancer Institute
Malignant Solid Tumor
A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours.
This is a phase 1 open label, 4 treatment, 4 sequence and 4 period crossover study in subjects with solid tumours no longer responding to, or eligible for standard therapies, and for whom there are no additional standard…
- Trial name
- IVIVC (NCT03553108)
- Testing
- Olaparib Treatment A, Olaparib Treatment B, Olaparib Treatment C
- Where
- 3 sites in Belgium
- Volunteers
- 18 people
- Sponsor
- AstraZeneca
Metastatic Malignant Solid Neoplasm
Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors
This phase I trial studies how well ibrutinib and nivolumab work in treating participants with solid tumors that have spread to other places in the body.
- Trial name
- NCT03525925
- Testing
- Ibrutinib, Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Oligometastatic Malignant Solid Neoplasm
Total RadIoTherapy of Oligometastatic caNcerS
This is a Phase III non-blinded randomized study evaluating patients with oligometastatic cancers (up to 10 metastases). Subjects are randomized 1:1 to stereotactic ablative radiotherapy (SABR) plus standard of care therapies…
- Trial name
- TRITONS (NCT06587490)
- Testing
- stereotactic ablative radiotherapy
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of California, San Diego
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
This phase II ComboMATCH treatment trial tests the usual treatment of chemotherapy (paclitaxel) plus ipatasertib in patients with solid tumor cancers that that cannot be removed by surgery (unresectable), has spread to nearby…
- Conditions
- Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT05554380
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 209 sites in United States, Puerto Rico
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms Malignant
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
This is an open-label, two-part study to evaluate the safety and tolerability of combination treatment with dalotuzumab + MK-2206, dalotuzumab + MK-0752, or dalotuzumab + ridaforolimus (MK-8669).
- Trial name
- NCT01243762
- Testing
- dalotuzumab, MK-0752, ridaforolimus
- Volunteers
- 47 people
- Sponsor
- Merck Sharp & Dohme LLC
Unresectable Malignant Neoplasm, Bulky Tumor
Proton and Proton-Photon Hybrid Partial Stereotactic Ablative Boost Radiotherapy (P-SABR) for Unresectable Large Tumors
This prospective, multicenter, observational cohort study will enroll 60 adults with unresectable larege tumors (longest diameter > 5 cm) who receive one of two treatment modes: (A) proton P-SABR, in which both the proton…
- Conditions
- Unresectable Malignant Neoplasm, Bulky Tumor, Solid Tumor
- Trial name
- LARGE-Proton (NCT07818798)
- Testing
- Proton P-SABR, Proton-Photon Hybrid P-SABR
- Volunteers
- 60 people
- Sponsor
- Peking University First Hospital
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Acceptance and Commitment Therapy and Compassion-Based Virtual Group Therapy to Improve Psychological Wellbeing in Patients With Cancer
This clinical trial tests how well acceptance and commitment therapy and compassion based virtual group therapy works to improve psychological wellbeing, such as compassion, understanding, and flexibility, in patients with…
- Trial name
- NCT06246955
- Testing
- Behavioral Intervention: Group Therapy Session, Survey Administration
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Mayo Clinic
Anal Carcinoma, Bladder Carcinoma
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and…
- Conditions
- Anal Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma
- Trial name
- NCT07118176
- Testing
- Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
B7-H3-positive Advanced Malignant Solid Tumors Advanced Primary Peritoneal Tumors or Secondary Abdominal Metastatic Malignant Solid Tumors
MT027 in Patients With Advanced Peritoneal Malignancies or Abdominal Metastatic Solid Tumors
This is an open-label, single-arm phase I dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of MT027 in patients with advanced primary peritoneal malignancies…
- Trial name
- NCT06912152
- Testing
- MT027 CAR-T cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Zhejiang University
Solid Tumors
A Phase 1 Study of HDM2017 in Advanced Solid Tumors
This is a phase I clinical study. All subjects are patients with advanced solid tumors. The purpose of this study is to to evaluate the safety, tolerability, pharmacokinetic (PK) characteristics, and preliminary antitumor…
- Trial name
- NCT07274085
- Testing
- HDM2017
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Cancer
Real-World Study of Young Patients With Solid Tumors in China
To evaluate organ preservation rates, fertility preservation, and long-term quality of life after treatment among young patients.
- Trial name
- NCT07708935
- Testing
- Ages 18-40
- Where
- China
- Volunteers
- 12,000 people
- Sponsor
- Fudan University
Neoplasm Malignant
Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients
Primary Objective: In the dose escalation: to determine the maximum tolerated dose (MTD) of SAR125844. In the expansion cohort: to evaluate the preliminary anti-tumoral effect of SAR125844 in patients with measurable and MET gene…
- Trial name
- SARMETA (NCT01657214)
- Testing
- SAR125844
- Where
- 8 sites in Japan, South Korea
- Volunteers
- 70 people
- Sponsor
- Sanofi
Advanced Solid Tumor, Cancer
Personalized Neoantigen-pulsed Autologous Dendritic Cell Injections for Malignant Solid Tumors
This is a prospective, single-center, open-label, real-world clinical study designed to evaluate the safety, efficacy, and immunogenicity of Personalized neoantigen-pulsed autologous dendritic cell Injections （ZSNeo-DC）in…
- Conditions
- Advanced Solid Tumor, Cancer, Malignant Solid Tumor
- Trial name
- ZSNeo-DC-RWS (NCT07752953)
- Testing
- Personalized neoantigen-pulsed autologous dendritic cell Injections （ZSNeo-DC）, Immune Checkpoint Inhibitors
- Where
- China
- Volunteers
- 100 people
- Sponsor
- ZSky Biotech Inc
Neuroblastoma in Children, Neuroblastoma, Recurrent, Refractory
Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
This is an Expanded Access Program (EAP) that will give the participants access to the drug SL-28 before it is approved by the FDA.
- Conditions
- Neuroblastoma in Children, Neuroblastoma, Recurrent, Refractory, Advanced Cancer, Advanced Malignant Neoplasm
- Trial name
- NCT06872489
- Testing
- SL-28.
- Sponsor
- Second Life Therapeutics
Anxiety, Depression
Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies
This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started…
- Conditions
- Anxiety, Depression, Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT07336238
- Testing
- Psychotherapy, Psilocybin, Survey Administration
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Washington
Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
This phase I trial studies the side effects and best dose of pembrolizumab and recombinant interleukin-12 in treating patients with solid tumors.
- Trial name
- NCT03030378
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 27 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Safety and Tolerability of NCP-IL-22BP mRNA in Advanced Solid Tumors
This is a phase I, open-label, single-arm, single-center, dose-escalation study to evaluate the safety, tolerability, and preliminary anti-tumor activity of NCP-IL-22BP mRNA, a non-cationic peptide-delivered mRNA encoding…
- Trial name
- NCT07562815
- Testing
- 25 μg NCP-IL-22BP mRNA, 50 μg NCP-IL-22BP mRNA, 100 μg NCP-IL-22BP mRNA
- Where
- China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Advanced Solid Tumors, Head and Neck Cancer
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Phase 1a/1b does-escalation study of cabiralizumab alone and with nivolumab in advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- FPA008-003 (NCT02526017)
- Testing
- Cabiralizumab, Nivolumab
- Where
- 39 sites in United States
- Volunteers
- 313 people
- Sponsor
- Five Prime Therapeutics, Inc.
Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors.
- Conditions
- Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT06126276
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 194 sites in United States, Puerto Rico
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.